ImmuPharma plc (LON:IMM – Get Free Report) shares reached a new 52-week low on Tuesday. The company traded as low as GBX 2.51 and last traded at GBX 2.80, with a volume of 2,026,019 shares trading hands. The stock had previously closed at GBX 2.60.
ImmuPharma Price Performance
The company’s fifty day simple moving average is GBX 3.48 and its 200 day simple moving average is GBX 4.50. The firm has a market capitalization of £16.13 million, a PE ratio of -3.11 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last released its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. On average, analysts anticipate that ImmuPharma plc will post -339.00 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
